COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ICU Cell Saver to Reduce Blood Transfusions in Cardiac

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00950547
Recruitment Status : Completed
First Posted : July 31, 2009
Last Update Posted : January 5, 2010
Information provided by:
Cardiochirurgia E.H.

Brief Summary:

PURPOSE: Autotransfusion devices may be employed in cardiac surgery to decrease allogenic blood requirements. Limitations of previous trials include the use of cell saver systems in selected high risk patients only or the lack of blood transfusion-sparing strategies. The aim of this prospective randomized study is to evaluate the efficacy of cell salvage CardioPAT routinely used in cardiac surgery.

METHODS: The investigators will randomize 350 patients in two groups: group 1 receives a CardioPAT cell saver device (175 patients), group 2 doesn't receive any cell saver device. The incidence of allogenic blood transfusion and clinical outcome in both groups are evaluated.

Condition or disease Intervention/treatment Phase
Blood Transfusion Cardiac Surgery Device: CARDIOPAT Device: Traditional Chest Drains Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Routinely Use of CardioPAT Cell Saver in Cardiac Surgery: A Prospective Randomized Study Focused on Allogenic Blood Transfusion and Clinical Outcome
Study Start Date : August 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Control
Traditional Chest drains
Device: Traditional Chest Drains
Chest drains as usual with no possibility to reinfuse lost blood

Experimental: CARDIOPAT
CARDIOPAT Cell Saver after Surgery
Cell Saver System at bedside for ICU stay

Primary Outcome Measures :
  1. Number of Transfusions per patient [ Time Frame: 10 days after surgery ]

Secondary Outcome Measures :
  1. Mortality [ Time Frame: 30 days after surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients presenting for cardiac Surgery

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00950547

Layout table for location information
Cardiochirurgia European Hospital
Rome, Italy, 00152
Sponsors and Collaborators
Cardiochirurgia E.H.
Layout table for additonal information
Responsible Party: Saverio Nardella, Cardiochirurgia E.H. Identifier: NCT00950547    
Other Study ID Numbers: 00-02
First Posted: July 31, 2009    Key Record Dates
Last Update Posted: January 5, 2010
Last Verified: January 2010
Keywords provided by Cardiochirurgia E.H.:
Blood Transfusion
Cell Saver
Cardiac Surgery
Evaluate the efficacy of cell salvage CardioPAT routinely used in cardiac surgery in reducing blood transfusions.